Clinical-stage durability-focused obesity pipeline: ALV-100 GIPR antagonist + GLP-1R agonist Phase 2 ready (licensed from Gmax Biopharm), ALV-200 amylin agonist IND-enabling, oral amylin candidates; cumulative $197M oversubscribed Series A
No detailed funding rounds available.
Total known funding: